RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Integrating the patient voice into pharmacoepidemiology research on the benefits and harms of medication
Majid, T., Heath, N., Kim, J., West, S. L., & dosReis, S. (2022). Integrating the patient voice into pharmacoepidemiology research on the benefits and harms of medication. Journal of Public Health-heidelberg, 30(12), 2963-2969. Advance online publication. https://doi.org/10.1007/s10389-021-01477-2
Purpose Patient engagement has traditionally been limited to involving patients in decision-making regarding their healthcare choices. The goal of this paper was to assess patients' perspectives on how they might be involved as a research partner in the design and implementation of pharmacoepidemiology research studies. Methods Qualitative research methods were used to elicit patient perspectives on their involvement in pharmacoepidemiologic research. A total of 20 patients participated in five focus groups held from April to August 2016. Each focus group represented one of five chronic conditions, namely: human immunodeficiency virus/acquired immunodeficiency syndrome (HIV)/(AIDS), diabetes, mental health conditions, mild cognitive impairment/Alzheimer's disease (AD), and cardiovascular disease (CVD)/hypertension. A semi-structured field guide was used to elicit views on drug safety and effectiveness and to identify which aspects of the design and implementation of a research study individuals felt most comfortable contributing to. The discussions were audio-recorded, transcribed verbatim, and analyzed following a grounded theory approach to identify the key themes that consequently emerged. Results For the most part, individuals equated safety with side-effects. There were several dimensions of effectiveness that corresponded with biological, clinical, and psychological aspects of well-being. Most individuals (84%) were comfortable deciding what information should be collected, and 74% felt they could help researchers select target outcomes to study. Fewer (58%) were confident they could advise on selecting comparator drugs. Conclusion There is a need for training the patient community and for adapting existing patient engagement standards to expand patient involvement in pharmacoepidemiologic research.